Belgium Finland Italy Spain Switzerland
Project ongoing
Analysis of the shortcomings and difficulties of currently authorised SARS-CoV-2 vaccines
The main aim of the SOLVE project is to decipher the mechanisms involved in inducing long-term immunity by directly comparing vaccine platforms, and to develop new vaccine concepts. The ultimate aim is to overcome the shortcomings and difficulties of the currently licensed SARS-CoV-2 vaccines.
In addition, the project will address crucial social issues relating to the acceptability of major vaccination campaigns and approaches to improving the implementation of the next generation of vaccines as part of a preparedness plan.
The implementation of second-generation vaccines, whose durability and safety have been demonstrated, must not be compromised by reluctance to use vaccines.
This pillar will focus on :
i) stakeholder involvement and empowerment, including the acceptability of vaccines and their characteristics ;
ii) regulatory integration of the preparation concept.
This last objective will be the focus of considerable effort and resources on the part of the consortium. One of the expected outcomes will be the definition of targeted vaccine education and regulatory strategies to accelerate the introduction of new vaccines to improve pandemic preparedness.
Melanie Prague
Melanie.prague@u-bordeaux.fr
Linda Wittkop
Linda.wittkop@u-bordeaux.fr
Anton Ottavi
anton.ottavi@u-bordeaux.fr
Discover our activities
in research and teaching
of Bordeaux's university sites.
. University of Bordeaux
. Institute of Public Health, Epidemiology and Development (Isped)
. Bordeaux Population Health Research Center (BPH)
. Bordeaux School of Economics (BSE)
. Sciences Po Bordeaux
Click on the names of the countries where we operate below the map!
